Table 2 Univariable Cox regression analysis of risk factors for the outcomes stroke, bleeding, and drug discontinuation

Age^a

0.98 (0.90–1.06)

0.59

1.03 (0.97–1.09)

0.30

0.99 (0.96–1.02)

0.54

Female sex

6.45 (0.75–55.2)

0.09

0.95 (0.36–2.56)

0.93

1.01 (0.59–1.75)

0.96

BMI^a

0.96 (0.81–1.13)

0.63

1.00 (0.92–1.10)

0.96

0.99 (0.94–1.04)

0.65

Congestive heart failure

2.00 (0.40–9.94)

0.40

1.15 (0.42–3.18)

0.78

1.28 (0.73–2.23)

0.39

Hypertension

24.2 (0.00–999)

0.60

23.8 (0.01–999)

0.42

0.60 (0.28–1.28)

0.18

Diabetes

2.42 (0.49–12.0)

0.28

1.13 (0.39–3.27)

0.82

2.31 (1.32–4.02)

0.003

Stroke/TIA/systemic embolism

18.5 (2.16–159)

0.008

0.76 (0.22–2.69)

0.67

0.76 (0.38–1.53)

0.44

Vascular disease

8.33 (0.97–71.3)

0.05

0.62 (0.21–1.82)

0.39

1.16 (0.67–2.00)

0.61

CHA₂DS₂–VASC Score^a

2.06 (1.27–3.35)

0.004

1.03 (0.77–1.37)

0.85

1.05 (0.90–1.21)

0.57

History of bleeding

0.85 (0.10–7.27)

0.88

1.17 (0.33–4.15)

0.81

2.51 (1.44–4.37)

0.001

HAS-BLED Score^a

1.61 (0.90–2.87)

0.11

1.18 (0.77–1.80)

0.45

1.14 (0.92–1.42)

0.22

Venous thromboembolism

2.26 (0.26–19.4)

0.46

0.87 (0.11–6.64)

0.89

1.29 (0.51–3.26)

0.59

Active cancer/history of cancer

0.04 (0.00–330)

0.48

1.24 (0.35–4.40)

0.74

1.15 (0.62–2.12)

0.66

OAC-naïve at baseline

0.05 (0.00–999)

0.69

0.94 (0.12–7.23)

0.95

0.78 (0.31–1.97)

0.60

Platelet count^a

1.00 (0.99–1.01)

0.71

1.00 (0.99–1.01)

0.60

1.00 (0.99–1.00)

0.34

Hemoglobin^a

0.80 (0.52–1.22)

0.29

1.05 (0.81–1.37)

0.71

0.89 (0.79–1.02)

0.08

Hematocrit^a

0.95 (0.81–1.11)

0.51

1.01 (0.91–1.11)

0.86

0.96 (0.92–1.01)

0.11

Leucocyte count^a

1.02 (0.91–1.13)

0.77

0.82 (0.63–1.06)

0.12

1.02 (1.00–1.05)

0.041

eGFR^a

0.97 (0.93–1.01)

0.17

0.98 (0.96–1.01)

0.21

1.01 (1.00–1.02)

0.27

HbA1c^a

1.71 (1.20–2.45)

0.003

1.13 (0.75–1.72)

0.54

1.31 (0.87–1.98)

0.20